Astellas submits MAA to EMA for enzalutamide
The submission is based on Phase 3 AFFIRM trial of enzalutamide in post-chemotherapy prostate cancer patients in which seizure was reported in less than 1% of enzalutamide-treated patients.
Telix Pharmaceuticals has officially opened a radiopharmaceutical research, manufacturing, and treatment facility in Melbourne, Australia, to expedite the delivery of new treatments for cancer.
EPS is offering analytical services, such as nuclear magnetic resonance spectroscopy (NMR) and liquid chromatography-mass spectrometry (LC-MS), and microbiological testing such as comprehensive drug resistance profiling and biofilm